HemaSphere (Aug 2023)
PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)
- Sarah A. Holstein,
- Hira Mian,
- Cyrille Touzeau,
- Edwin Kingsley,
- Dan Vogl,
- Richard Zuniga,
- Kaveri Suryanarayan,
- Shining Wang,
- Laura Thesillat-Versmee,
- Yuyin Liu,
- Tian Chen,
- Yefei Zhang,
- Xavier Parot,
- Hans C. Lee
Affiliations
- Sarah A. Holstein
- 1 University of Nebraska Medical Center, Omaha, NE, United States
- Hira Mian
- 2 McMaster University, Hamilton, Ontario, Canada
- Cyrille Touzeau
- 3 Centre Hospitalier Universitaire de Nantes, Nantes, France
- Edwin Kingsley
- 4 Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States
- Dan Vogl
- 5 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States
- Richard Zuniga
- 6 New York Cancer & Blood Specialists, New York, NY, United States
- Kaveri Suryanarayan
- 7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States
- Shining Wang
- 7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States
- Laura Thesillat-Versmee
- 7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States
- Yuyin Liu
- 7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States
- Tian Chen
- 7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States
- Yefei Zhang
- 7 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States
- Xavier Parot
- 8 Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, United States
- Hans C. Lee
- 9 The University of Texas MD Anderson Cancer Center, Houston, TX, United States
- DOI
- https://doi.org/10.1097/01.HS9.0000975280.98608.35
- Journal volume & issue
-
Vol. 7
p. e9860835
Abstract
No abstracts available.